| Textiles, Apparel & Luxury Goods Industry | Consumer Discretionary Sector | Shu-Hsuan Tsai CEO | TWSE Exchange | TW0001451003 ISIN |
| TW Country | - Employees | 16 Apr 2026 Last Dividend | 29 Sep 2017 Last Split | - IPO Date |
Maxigen Biotech Inc. is a dynamic entity in the biomedical sector, focusing on the research, development, production, and sales of implantable medical devices and cosmetic products. With its operations spanning across Taiwan, America, Europe, Asia, and other international markets, the company has carved a niche for itself in two primary segments: Biomedical Products and Consumer Products. Since its inception in 1998, Maxigen Biotech Inc. has established its headquarters in Taoyuan City, Taiwan, marking its presence as a key player in the global market.
Maxigen Biotech Inc. offers a diverse portfolio of products and services designed to meet the needs of patients and consumers worldwide. These include:
In addition to its focus on biomedical products, Maxigen Biotech Inc. also engages in the manufacturing and sales of beauty care products, further expanding its reach in the consumer market.